President Trump intends to sign an executive order to streamline regulations around drug manufacturing in the U.S., the Washington Post’s Natalie Allison reports, citing two White House officials who spoke on the condition of anonymity. The move comes ahead of potential pharma tariffs this summer, Allison notes. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump urges drugmakers to accept lower prices on prescriptions, Bloomberg says
- Johnson & Johnson announces new data from Phase 3 QUASAR study of tremfya
- Johnson & Johnson announces new data from Phase 3 ASTRO study of tremfya
- Johnson & Johnson’s Promising TAR-200 Platform Drives Buy Rating Amid Strong Bladder Cancer Treatment Data and Market Potential
- Johnson & Johnson Stock (JNJ) Perks Up as it Mulls $2.5B Purchase of Sonic Beam Cancer Fighting MedTech